phase of the protocol. Experimental parameters measured included left ventricular developed pressure, myocardial CK and norepinephrine release, mitochondrial respiratory control index, myocardial energy metabolism (ATP levels), and redox state (NADPH/NADP + ). The data obtained demonstrated ivabradine ameliorated ischemia reperfusion injury by all indices measured and that pacing the hearts at 180/min throughout abolished ivabradine's protective effects. Accordingly, the authors conclude, since the drug has no known negative inotropic effects 8 , that its principal mechanism of action is to reduce heart rate, especially very early in ischemia, and thereby mitigate ischemic damage by favorably impacting the myocardial oxygen supply/demand balance.
The authors consider an alternate mechanism based on reduced sodium influx resulting from I f current blockade with subsequent enhancement of calcium efflux at the level of the sarcolemmal Na+-Ca+ exchanger 9 . They note: "This could explain the reduction in the rise in diastolic pressure during ischaemia and reperfusion. Less cytosolic calcium would also facilitate mitochondrial ATP production during reperfusion due to competition for the restored mitochrondrial ∆ψ for calcium accumulation or ATP production 10 . This would explain the better energy recovery during reperfusion with ivabradine treatment." The authors, however, dismiss this explanation as improbable, arguing in effect that the time course of their experiments is too short to permit ischemia-induced "re-expression of I f channels in the myocyte" in "a major part 
